Role of in vivo imaging of the central nervous system for developing novel drugs

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 51, Issue 2, 2007, Pages 164-181

  Rueger, M A ^a   Kracht, L W ^a   Hilker, R ^a   Thiel, A ^a   Sobesky, J ^a   Winkeler, A ^a   Thomas, A V ^a   Heneka, M T ^a   Graf, R ^a   Herholz, K ^a   Heiss, W D ^a   Jacobs, Andreas H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Central nervous system; Computed tomography; Drugs; Magnetic resonance imaging; Tomography, emission computed

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; AMYLOID BETA PROTEIN[1-42]; ANGIOGENESIS INHIBITOR; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINESTERASE INHIBITOR; CONTRAST MEDIUM; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; FIBRINOLYTIC AGENT; FLUMAZENIL C 11; FLUORODEOXYGLUCOSE F 18; FLUOROTYROSINE C 11; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; LOMUSTINE; METHYLMETHIONINE C 11; MONOAMINE OXIDASE B INHIBITOR; N METHYL 2 (4' METHYL AMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE C 11; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; PLACEBO; PRAMIPEXOLE; PROCARBAZINE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT NERVE GROWTH FACTOR; ROPINIROLE; TEMOZOLOMIDE; TYROSINE C 11; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VINCRISTINE;

ALZHEIMER DISEASE; BRAIN DEPTH STIMULATION; BRAIN ISCHEMIA; BRAIN TOMOGRAPHY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; DRUG RESEARCH; GENE THERAPY; HUMAN; IN VIVO STUDY; MENINGOENCEPHALITIS; MOLECULAR IMAGING; MULTIPLE CYCLE TREATMENT; NERVOUS SYSTEM TUMOR; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PAIN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FORECASTING; HUMANS; MOLECULAR PROBE TECHNIQUES; NUCLEAR MEDICINE; RADIOPHARMACEUTICALS;

EID: 34447559466     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (155)

1. Hilker R, Klein C, Hedrich K, Ozelius LJ, Vieregge P, Herholz K et al. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci Lett 2002;323:50-4.
2. Jacobs A, Voges J, Reszka R, Lercher M, Gossmann A, Kracht L et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 2001;358:727-9.
3. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC. Histopathology, classification, and grading of gliomas. Glia 1995;15:211-21.
4. Mariani L, Siegenthaler P, Guzman R, Friedrich D, Fathi AR, Ozdoba C et al. The impact of tumour volume and surgery on the outcome of adults with supratentorial WHO grade II astrocytomas and oligoastrocytomas. Acta Neurochir (Wien) 2004;146:441-8.
5. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate postradiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004;63:535-7.
6. Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217:377-84.
7. Vos MJ, Uitdehaag BM, Barkhof F, Heimans JJ, Baayen HC, Boogerd W et al. Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology 2003;60:826-30.
8. Jacobs AH, Voges J, Kracht LW, Dittmar C, Winkeler A, Thomas A et al. Imaging in gene therapy of patients with glioma. J Neurooncol 2003;65:291-305.
9. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32.
10. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
11. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK797/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-64.
12. Ludemann L, Hamm B, Zimmer C. Pharmacokinetic analysis of glioma compartments with dynamic Gd-DTPA-enhanced magnetic resonance imaging. Magn Reson Imaging 2000;18:1201-14.
13. Gossmann A, Helbich TH, Kuriyama N, Ostrowitzki S, Roberts TP, Shames DM et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 2002;15:233-40.
14. Provenzale JM, McGraw P, Mhatre P, Guo AC, Delong D. Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. Radiology 2004;232:451-60.
15. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029-36.
16. Mardor Y, Roth Y, Ochershvilli A, Spiegelmann R, Tichler T, Daniels D et al. Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. Neoplasia 2004;6:136-42.
17. Hein PA, Eskey CJ, Dunn JF, Hug EB. Diffusion-weighted imaging in the follow-up of treated high-grade glioma: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004;25:201-9.
18. Sinha S, Bastin ME, Wardlaw JM, Armitage PA, Whittle IR. Effects of dexamethasone on peritumoural oedematous brain: a DT-MRI study. J Neurol Neurosurg Psychiatry 2004;75:1632-5.
19. Mardor Y, Roth Y, Lidar Z, Jonas T, Pfeffer R, Maier SE et al. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 2001;61:4971-3.
20. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant ghoma: a phase I/II clinical study. J Neurosurg 2004;100:472-9.
21. Meyerand AM, Pipas JM, Mamourian A, Tosteson TD, Dunn JF. Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy. AJNR Am J Neuroradiol 1999;20:117-23.
22. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-4.
23. Herminghaus S, Pilatus U, Moller-Hartmann W, Raab P, Lanfermann H, Schlote W et al. Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 2002;15:385-92.
24. Croteau D, Scarpace L, Hearshen D, Gutierrez J, Fisher JL, Rock JP et al. Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery 2001;49:823-9.
25. Pirzkall A, McKnight TR, Graves EE, Carol MP, Sneed PK, Wara WW et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 2001;50:915-28.
26. Ross BD, Kim B, Davidson BL. Assessment of ganciclovir toxicity to experimental intracranial gliomas following recombinant adenoviral-mediated transfer of the herpes simplex virus thymidine kinase gene by magnetic resonance imaging and proton magnetic resonance spectroscopy. Clin Cancer Res 1995;1:651-7.
27. Nelson SJ. Magnetic resonance spectroscopic imaging. Evaluating responses to therapy for gliomas. IEEE Eng Med Biol Mag 2004;23:30-9.
28. Lehnhardt FG, Bock C, Rohn G, Ernestus RI, Hoehn M. Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed 2005;18:371-82.
29. Hakumaki JM, Poptani H, Sandmair AM, Yla-Herttuala S, Kauppinen RA. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: unplications for the in vivo detection of apoptosis. Nat Med 1999;5:1323-7.
30. Herholz K, Wienhard K, Heiss WD. Validity of PET studies in brain tumors. Cerebrovasc Brain Metab Rev 1990;2:240-65.
31. Jacobs AH, Dittmar C, Winkeler A, Garlip G, Heiss WD. Molecular imaging of gliomas. Mol Imaging 2002;1:309-35.
32. Heiss WD, Pawlik G, Herholz K, Wagner R, Goldner H, Wienhard K. Regional kinetic constants and cerebral metabolic rate for glucose in normal human volunteers determined by dynamic positron emission tomography of [18F]-2-fluoro-2-deoxy-D-glucose. J Cereb Blood Flow Metab 1984;4:212-23.
33. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000;41:661-81.
34. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977;28:897-916.
35. Heiss WD, Heindel W, Herholz K, Rudolf J, Bunke J, Jeske J et al. Positron emission tomography of fluorine-18-deoxyglucose and image-guided phosphorus-31 magnetic resonance spectroscopy in brain tumors. J Nucl Med 1990;31:302-10.
36. Herholz K, Heindel W, Luyten PR, denHollander JA, Pietrzyk U, Voges J et al. In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol 1992;31:319-27.
37. Herholz K, Pietrzyk U, Voges J, Schroder I, Halber M, Treuer H et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 1993;79: 853-8.
38. Barker FG, Chang SM, Valk PE, Pounds TR, Prados MD. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997;79:115-26.
39. Goldman S, Levivier M, Pirotte B, Brucher JM, Wilder D, Damhaut P et al. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 1996;78:1098-106.
40. Kim EE, Chung SK, Haynie TP, Kim CG, Cho BJ, Podoloff DA et al. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET. Radiographics 1992;12:269-79.
41. Wurker M, Herholz K, Voges J, Pietrzyk U, Treuer H, Bauer B et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 1996;23:583-6.
42. Brock CS, Young H, O'Reilly SM, Matthews J, Osman S, Evans H et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000;82:608-15.
43. De Witte O, Levivier M, Violon P, Salmon I, Damhaut P, Wikler D Jr. et al. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. Neurosurgery 1996;39:470-6.
44. Glantz MJ, Hoffman JM, Coleman RE, Friedman AH, Hanson MW, Burger PC et al. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol 1991;29:347-55.
45. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 2001;96:191-7.
46. Vlassenko AG, Thiessen B, Beattie BJ, Malkin MG, Blasberg RG. Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI. J Neurooncol 2000;46:249-59.
47. Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ, Di Chiro G. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg 1995;83:657-64.
48. Herholz K, Holzer T, Bauer B, Schroder R, voges J, Ernestus RI et al. 11C-methionine PE7 for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316-22.
49. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Degueldre C, Del Fiore G et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbort-11-methionine. J Nucl Med 1998;39:778-85.
50. Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002;29:176-82.
51. Pauleit D, Floeth F, Tellmann L, Hamacher K, Hautzel H, Muller HW et al. comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors. J Nucl Med 2004;45: 374-81.
52. Langen KJ, Muhlensiepen H, Holschbach M, Hautzel H, Jansen P, Coenen HH. Transport mechanisms of 3-[123I]iodo-alpha-methyl-L-tyrosine in a human glioma cell line: comparison with [3H]methyl]-L-methionine. J Nucl Med 2000;41:1250-5.
53. Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A et al. Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30:868-73.
54. De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746-50.
55. Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Langstrom B et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer 2001;92:1541-9.
56. Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S. Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol 2005;71:161-8.
57. Herholz K, Kracht LW, Heiss WD. Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 2003;13:269-71.
58. Galldiks N, Kracht LW, Burghaus L, Thomas A, Jacobs AH, Heiss WD et al. Use of (11)C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging 2006;33:516-24.
59. Popperl G, Gotz C, Rachinger W, Gildehaus FJ, Tonn JC, Tatsch K. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 2004;31:1464-70.
60. Popperl G, Goldbrunner R, Gildehaus FJ, Kreth FW, Tanner P, Holtmannspotter M et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 2005;32:1018-25.
61. Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005;46:1948-58.
62. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM et al. Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nat Med 1998;4:1334-6.
63. Mankoff DA, Dehdashti F, Shields AF. Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia. 2000;2:71-88.
64. Voges J, Reszka R, Gossmann A, Dittmar C, Richter P, Garlip G et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol 2003;54:479-87.
65. Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 1996;274:1197-9.
66. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8.
67. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003;302:819-22.
68. Hutchinson M, Raff U, Lebedev S. MRI correlates of pathology in parkinsonism: segmented inversion recovery ratio imaging (SIR-RIM). Neuroimage 2003;20:1899-902.
69. Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson's disease arid atypical parkinsonian syndromes. Neurology 2003;60:74-7.
70. Schulz JB, Skalej M, Wedekind D, Luft AR, Abele M, Voigt K et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999;45:65-74.
71. Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Mueller J et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60:922-7.
72. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002;73:517-23.
73. Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995;59:597-600.
74. Rinne JO, Bergman J, Ruottinen H, Haaparanta M, Eronen E, Oikonen V et al. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease. Synapse 1999;31:119-24.
75. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;15:692-8.
76. Fischman AJ, Bonab AA, Babich JW, Livni E, Alpert NM, Meltzer PC et al. [(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse 2001;39:332-42.
77. Hilker R, Klein C, Ghaemi M, Kis B, Strotmann T, Ozelius LJ et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001;49:367-76.
78. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999;45:577-82.
79. Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch. Neurol 2005;62:378-82.
80. Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P et al. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 2001;16:608-15.
81. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003;54:93-101.
82. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-61.
83. Hilker R, Voges J, Ghaemi M, Lehrke R, Rudolf J, Koulousakis A et al. Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. Mov Disord 2003;18:41-8.
84. Hilker R, Voges J, Weisenbach S, Kalbe E, Burghaus L, Ghaemi M et al. Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease. J Cereb Blood Flow Metab 2004;24:7-16.
85. Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999;2:1137-40.
86. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-9.
87. Schapira AH. Present and future drug treatment for Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:1472-8.
88. Linazasoro G. Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. Mov Disord 2004;19:743-54.
89. Clarke CE. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. Lancet Neurol 2004;3:466-74.
90. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508.
91. Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001;345:956-63.
92. Benazzouz A, Hallett M. Mechanism of action of deep brain stimulation. Neurology 2000;55:S13-S16.
93. Hilker R, Portman AT, Voges J, Staal MJ, Burghaus L, van Laar T et al. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 2005;76:1217-21.
94. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996;380:252-5.
95. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995;373:335-9.
96. Kirik D, Rosenblad C, Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 2000;12:3871-82.
97. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60:69-73.
98. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-95.
99. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59:459-66.
100. During MJ, Naegele JR, O'Malley KI, Geller AI. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994;266:1399-403.
101. Kaplitt MG, Leone P, Samutski RJ, Xiao X, Pfaff DW, O'Malley KL et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994;8:148-54.
102. Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002;298:425-9.
103. During MJ, Kaplitt MG, Stern MB, Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 2001;12:1589-91.
104. Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephatic tissue in a patient with Parkinsons disease. N Engl J Med 1995;332:1118-24.
105. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-14.
106. Kim JH, Auerbach JM, Rodriguez-Gomez JA, Velasco I, Gavin D, Lumelsky N et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002;418:50-6.
107. Behrstock S, Svendsen CN. Combining growth factors, stem cells, and gene therapy for the aging brain. Ann N Y Acad Sci 2004;1019:5-14.
108. De Lacoste MC, White CL, III. The role of cortical connectivity in Alzheimer's disease pathogenesis: a review and model system. Neurobiol Aging 1993;14:1-16.
109. Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 2003;84:1215-36.
110. Kilgard MP, Merzenich MM. Cortical map reorganization enabled by nucleus basalis activity. Science 1998;279:1714-8.
111. Conner JM, Culberson A, Packowski C, Chiba AA, Tuszynski MH. Lesions of the Basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity associated with motor skill learning. Neuron 2003;38:819-29.
112. Press GA, Amaral DG, Squire LR. Hippocampal abnormalities in amnesic patients revealed by high-resolution magnetic resonance imaging. Nature 1989;341:54-7.
113. Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Saint Louis LA et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 2000;95:721-5.
114. Jack CR Jr., Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002;58:750-7.
115. Mosconi L, De Santi S, Rusinek H, Convit A, de Leon W. Magnetic resonance and PET studies in the early diagnosis of Alzheimer's disease. Expert Rev Neurother 2004;4:831-49.
116. Jack CR Jr., Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397-403.
117. Herholz K. PET studies in dementia. Ann Nucl Med 2003;17:79-89.
118. Friedland RP, Brun A, Budinger TF. Pathological and positron emission tomographic correlations in Alzheimer's disease. Lancet 1985;1:228.
119. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
120. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-16.
121. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 2003;54:343-51.
122. Heiss WD, Habedank B, Klein JC, Herholz K, Wienhard K, Lenox M et al. Metabolic rates in small brain nuclei determined by high-resolution PET. J Nucl Med 2004;45:1811-5.
123. Jacobs AH, Winkler A, Castro MG, Lowenstein P. Human gene therapy and imaging in neurological diseases. Eur J Nucl Med Mol Imaging 2005;32 Suppl. 2:S358-S383.
124. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J. Comp Neurol 1983;214:170-97.
125. Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997;349:1805-9.
126. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745-8.
127. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Davis JG et al. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett 2005; 380:127-32.
128. Herholz K, Weisenbach S, Zundorf G, Lenz O, Schroder H, Bauer B et al. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage 2004;21:136-43.
129. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001;7:369-72.
130. Bacskai BJ, Klunk WE, Mathis CA, Hyman BT. Imaging amyloid-beta deposits in vivo. J Cereb Blood Flow Metab 2002;22:1035-41.
131. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19.
132. Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF et al. Four-dimensional multiphoton imaging of brain entry, amylord binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A 2003;100:12462-7.
133. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE et al. In vivo measurement of activated microglia in dementia. Lancet 2001;358:461-7.
134. Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T et al. Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 2006;26:1343-54.
135. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med 1999;341:1670-9.
136. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003;160:2003-11.
137. Mega MS, Dinov ID, Porter V, Chow G, Reback E, Davoodi P et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol 2005;62:721-8.
138. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237:1154-62.
139. Fischer W, Wictorin K, Bjorklund A, Williams LR, Varon S, Gage FH. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987;329:65-8.
140. Rosenberg MB, Friedmann T, Robertson RC, Tuszynski M, Wolff JA, Breakefield XO et al. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science 1988;242:1575-8.
141. Tuszynski MH, HS U, Amaral DG, Gage FH. Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci 1990;10:3604-14.
142. Eriksdotter JM, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9:246-57.
143. Tuszynski MH, Thal L, Pay M, Salmon DP, HS U, Bakay R et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005;11:551-5.
144. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62.
145. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563-72.
146. Schenk D, Hagen M, Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 2004;16:599-606.
147. Heiss WD, Graf R, Wienhard K, Lottgen J, Saito R, Fujita T et al. Dynamic penumbra demonstrated by sequential multitracer PET after middle cerebral artery occlusion in cats. J Cereb Blood Flow Metab 1994;14:892-902.
148. Heiss WD. Best measure of ischemic penumbra: positron emission tomography. Stroke 2003;34:2534-5.
149. Sobesky J, Zaro WO, Lehnhardt FG, Hesselmann V, Neveling M, Jacobs A et al. Does the mismatch match the penumbra? Magnetic resonance imaging and positron emission tomography in early ischemic stroke. Stroke 2005;36:980-5.
150. Sobesky J, Zaro WO, Lehnhardt FG, Hesselmann V, Thiel A, Dohmen C et al. Which time-to-peak threshold best identifies penumbral flow? A comparison of perfusion-weighted magnetic resonance imaging and positron emission tomography in acute ischemic stroke. Stroke 2004;35:2843-7.
151. Heiss WD, Kracht LW, Thiel A, Grond M, Pawlik G. Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain 2001;124:20-9.
152. Markus R, Reutens DC, Kazui S, Read S, Wright P, Chambers BR et al. Topography and temporal evolution of hypoxic viable tissue identified by 18F-fluoromisonidazole positron emission tomography in humans after ischemic stroke. Stroke 2003;34: 2646-52.
153. Hjort N, Butcher K, Davis SM, Kidwell CS, Koroshetz WJ, Rother J et al. Magnetic resonance imaging criteria for thrombolysis in acute cerebral infarct. Stroke 2005;36:388-97.
154. Arvidsson A, Collin T, Kirik D, Kokaia Z, Undvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 2002;8:963-70.
155. Nakatomi H, Kuriu T, Okabe S, Yamamoto S, Hatano O, Kawahara N et al. Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. Cell 2002;110:429-41.